ABSTRACT
This chapter focuses on the use of intravenous immunoglobulin (IVIG) in the treatment of autoimmune mucocutaneous blistering diseases (AMBDs). In order to avoid speculation and controversy, only published data on these clinical entities are discussed. The principal contents of this chapter are the published experiences of treating 125 patients suffering from AMBDs with IVIG, at one center in the USA.
